### **Overview** Ind-Swift Laboratories Ltd. is an Indian multinational pharmaceutical company headquartered in Chandigarh, India. Originally established as a leading **Active Pharmaceutical Ingredient (API)** manufacturer, the company has undergone a transformative strategic shift to reposition itself as a **research-led, formulations-focused enterprise**, operating with a **debt-free balance sheet** post-merger in July 2025. The company now operates as a unified, export-driven formulations business with strong global regulatory compliance, R&D capabilities, and a diversified international presence. --- ### **Strategic Transformation (2023–2025)** - **Divestment of API and CRAMS Business (2023–2025):** - Sold its API and CRAMS business via a slump-sale to **PI Industries/Synthimed Labs Pvt. Ltd.** for **₹1,650 crore** in February 2025. - Proceeds were used to **repay all debt** (~₹1.2 billion) for both Ind-Swift Laboratories and its associate company, **Ind Swift Limited**. - The transaction marked a clear exit from low-margin API manufacturing and enabled strategic reinvestment in high-growth **formulations**. - **Amalgamation & Merger (Completed July 2025):** - Completed the merger with **Ind Swift Limited**, a legacy formulations player since 1986, to consolidate manufacturing, R&D, and commercial capabilities. - The merged entity is now **debt-free, cash-rich, and streamlined**, enabling acceleration of formulation-based growth and strategic expansion. - **Re-entry into Formulations:** - The merger allows Ind-Swift to return to its core **formulations roots**, leveraging decades of legacy in dosage form manufacturing. - Focus now on **higher-margin, complex generics**, including **injectables, PFS, hormones, and specialty products**. --- ### **Business Segments & Manufacturing** #### **1. Global Business Unit (GBU) – Export-Oriented Facility** - Located in **Derabassi, Punjab**, on 27,328 sq. m. of freehold land. - **100% export-focused**, serving **regulated and semi-regulated markets** (US, EU, UK, Canada, Australia, South Africa). - **Dosage Forms:** Tablets, hard gelatin capsules, granules in sachets, creams, ointments. - **Key Capabilities:** - End-to-end contract manufacturing - Day-one generic launches - Co-development & dossier out-licensing - Fast site transfers: **150–180 days** from trial to validation - **Regulatory Approvals:** MHRA (UK), TGA (Australia), EU-GMP, WHO-GMP, MCC (South Africa). - **USFDA and ANVISA approvals in pipeline.** #### **2. Domestic Manufacturing Units** - **Samba (Jammu & Kashmir):** - Annual capacity: **1,080M tablets, 120M capsules, 120M ointments**. - Supplies both **domestic (India)** and **Rest of World (ROW)** markets. - **Jammu Unit:** - Supports plant-to-plant transfers for domestic needs and exports. - **Parwanoo and Mohali Facilities:** - Part of expanded manufacturing footprint post-merger. - **New Greenfield Facility (Mohali):** - Under development, designed to meet **USFDA and ANVISA** standards. - Will enhance dossier submissions and capacity for regulated markets. #### **3. Total Manufacturing Capacity (Integrated)** - **9.6 billion tablets**, **186 million capsules**, **184 million stick packs**, **30 million units of creams/ointments** annually. - **High-speed packaging lines** with camera inspection, serialization (Smart Tracker, SPAN), and tamper-evidence tech. --- ### **Global Business Strategy & Market Presence** #### **Exports & International Markets** - **Exports contribute ~75% of total revenue.** - Operates in **over 70 countries**, with **750+ marketing authorizations** globally. - Targeting **top-five brand rankings** in key international markets. #### **Key Regions & Expansion Plans** - **Europe:** Largest revenue contributor; key products include Atorva-Ezetimibe (launched day-one in 2024). - **Middle East & CIS:** Direct operations in **Dubai, Baku, Dushanbe**; recent launches in **Azerbaijan, Tajikistan**; triple-digit growth targeted. - **Africa:** Active in **Nairobi, Kampala, Dar es Salaam, Abidjan**; expansion planned into **Zambia, Rwanda, Zimbabwe, Togo**. Partnerships with tender authorities to supply emergency medicines. - **Latin America:** Expanding in **Peru, Colombia, Chile, Argentina**; new regulatory approvals and alliances underway; dedicated branding team to launch in Peru (FY2026). - **Asia-Pacific:** Stronghold in **Malaysia, Singapore, Thailand, Philippines, Hong Kong**. #### **Go-to-Market Strategy** - Tailored approaches for **semi-regulated and emerging markets**. - **Physical presence** being considered in select high-growth countries. - **Agile marketing + targeted infrastructure investments** for sustainable export-led growth. --- ### **Research & Development (R&D)** - **DSIR-recognized R&D centers** in **Chandigarh and Jammu**. - Employ **50+ scientists** across formulation, analytical, process optimization, and chemistry. - Core R&D Focus: - Novel Drug Delivery Systems (NDDS) - GR/DR, MUPS, coated granules, FDCs - **Injectables and topicals** (new focus areas) - In-house development of **non-infringing generics** - Achievements: - **Filed 1,915+ dossiers**, secured **520+ approvals** globally. - **Commercialized 750+ products**. - **100+ technology transfers** executed. - **Patented Clarithromycin Citrate** (US, Europe, India). - **First-to-market** launch of **Atorva-Ezetimibe** in Europe. - **Two patents filed** in FY24–25 for novel formulations. - **Pipeline:** Over **30 products** in development for US, EU, Canada; **3–5 nearing commercial launch** in 18–24 months. --- ### **Commercial & Branding Initiatives** #### **Domestic Business – India** - **Branded Generics Leader:** Portfolio of **700+ products** across cardiology, diabetology, gynaecology, dermatology, and paediatrics. - **Direct-to-Stockist (DTS)** model via CFA networks for wider reach. - **Ethical Division:** 15% YoY revenue growth; - Launched **Matravi** (Rs 9 crore in first 6 months). - Introduced **Anin PFS** – India’s first pre-filled syringe for gestational hormones. - **Agile Division:** Specialty generics (150 products); another **150-product generics vertical** planned for FY2026–27. - **New Delhi Office:** Dedicated team to position Ind-Swift among **Top 80 pharma firms (IQVIA)** in India. #### **Global Brands & Partnerships** - Trusted **contract manufacturing partner** for **Teva, Actavis, Stada, Viatris, Sandoz, Mylan, Wockhardt**. - Strategic alliances in brand marketing, co-development, and out-licensing. - **Day-one launch** of Atorva-Ezetimibe with leading EU generic partners. --- ### **Operations & Supply Chain Excellence** - **97% Delivered in Full, On Time (DIFOT)** rate – industry benchmark. - **Structured production process:** R&D batch → GMP validation → commercial scale. - **High-capacity, flexible lines** that reconfigure quickly for partner-specific requirements. - **End-to-end packaging compliance** with international traceability standards. --- ### **Financial Highlights (FY25)** - **Revenue:** ₹550 crore - **Pre-Tax Profit:** ₹41 crore - **Debt:** Fully repaid; **zero-debt balance sheet** post-merger. - **Revenue Model (Post-Merger):** - Exports (75%) - CDMO/contract manufacturing - Domestic branded formulations - **Investment in CPL cricket franchise** to build early presence in sports & entertainment.